Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice
ABSTRACT Background and objective The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyc...
Gespeichert in:
| Veröffentlicht in: | Respirology (Carlton, Vic.) Vic.), 2017-07, Vol.22 (5), p.905-912 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 912 |
|---|---|
| container_issue | 5 |
| container_start_page | 905 |
| container_title | Respirology (Carlton, Vic.) |
| container_volume | 22 |
| creator | Fonseca, Vanessa M.B. Milani, Thamires M.S. Prado, Rafael Bonato, Vania L.D. Ramos, Simone G. Martins, Flaviano S. Vianna, Elcio O. Borges, Marcos de C. |
| description | ABSTRACT
Background and objective
The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyces cerevisiae UFMG A‐905 in an allergic model of asthma.
Methods
Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, 1 week apart and challenged with OVA intranasally for 3 days. Mice were daily treated with S. cerevisiae UFMG A‐905 via gavaging needle 10 days before OVA sensitization and during challenges. After challenge, in vivo lung function was measured, and bronchoalveolar lavage (BAL) and lung inflammation were assessed.
Results
Oral treatment with S. cerevisiae UFMG A‐905 significantly decreased airway hyperresponsiveness, total cell number and the influx of eosinophils to the airway, inflammatory cell in the lung, mucus expression in epithelial cells and the levels of IL‐4, IL‐5 and IL‐13. Additionally, S. cerevisiae UFMG A‐905 restored the levels of IL‐10 and interferon (IFN)‐gamma, and increased the levels of IL‐17A.
Conclusion
Oral administration of S. cerevisiae UFMG A‐905 prevented the development of major asthma‐like characteristics in a mouse model.
Probiotics are a promising strategy for asthma prevention. We evaluated the effects of a yeast probiotic in ovalbumin‐challenged mice. Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevented the development of main asthma‐like characteristics, such as bronchial hyperresponsiveness, bronchoalveolar eosinophilia and airway and lung inflammation. |
| doi_str_mv | 10.1111/resp.12990 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1865820412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1865820412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3570-8171d8df8c8c16538b54aae5f8b2ffa04fbbf8b9ecb084a57ac8a449f1a082ea3</originalsourceid><addsrcrecordid>eNp9kMtKBDEQRYMovjd-gATciNCapJPu9FLEFyiKj6WE6kxFI_0Ykx5ldn6C3-iXGB114cLa1KU4XIpDyAZnuzzNXsA43uWiqtgcWeZSsoxrmc-nnIs8K8uqWiIrMT4yxnLF1CJZEpoXRcHZMrm7CNBQGLW-83EIMPi-o72j12DtA4S-nVqM1GLAZx89IL09Oj-m---vbxVTdJzO2A2RQtNguPeWQhweWqC-o623uEYWHDQR17_3Krk9Orw5OMnOLo5PD_bPMpurkmWal3ykR05bbXmhcl0rCYDK6Vo4B0y6uk65QlszLUGVYDVIWTkOTAuEfJVsz3rHoX-aYBxM66PFpoEO-0k0XBdKCya5SOjWH_Sxn4QufWd4JZhSQqgyUTszyoY-xoDOjINvIUwNZ-ZTuvmUbr6kJ3jzu3JStzj6RX8sJ4DPgBff4PSfKnN1eH05K_0AUmuNRQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920552257</pqid></control><display><type>article</type><title>Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Fonseca, Vanessa M.B. ; Milani, Thamires M.S. ; Prado, Rafael ; Bonato, Vania L.D. ; Ramos, Simone G. ; Martins, Flaviano S. ; Vianna, Elcio O. ; Borges, Marcos de C.</creator><creatorcontrib>Fonseca, Vanessa M.B. ; Milani, Thamires M.S. ; Prado, Rafael ; Bonato, Vania L.D. ; Ramos, Simone G. ; Martins, Flaviano S. ; Vianna, Elcio O. ; Borges, Marcos de C.</creatorcontrib><description>ABSTRACT
Background and objective
The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyces cerevisiae UFMG A‐905 in an allergic model of asthma.
Methods
Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, 1 week apart and challenged with OVA intranasally for 3 days. Mice were daily treated with S. cerevisiae UFMG A‐905 via gavaging needle 10 days before OVA sensitization and during challenges. After challenge, in vivo lung function was measured, and bronchoalveolar lavage (BAL) and lung inflammation were assessed.
Results
Oral treatment with S. cerevisiae UFMG A‐905 significantly decreased airway hyperresponsiveness, total cell number and the influx of eosinophils to the airway, inflammatory cell in the lung, mucus expression in epithelial cells and the levels of IL‐4, IL‐5 and IL‐13. Additionally, S. cerevisiae UFMG A‐905 restored the levels of IL‐10 and interferon (IFN)‐gamma, and increased the levels of IL‐17A.
Conclusion
Oral administration of S. cerevisiae UFMG A‐905 prevented the development of major asthma‐like characteristics in a mouse model.
Probiotics are a promising strategy for asthma prevention. We evaluated the effects of a yeast probiotic in ovalbumin‐challenged mice. Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevented the development of main asthma‐like characteristics, such as bronchial hyperresponsiveness, bronchoalveolar eosinophilia and airway and lung inflammation.</description><identifier>ISSN: 1323-7799</identifier><identifier>EISSN: 1440-1843</identifier><identifier>DOI: 10.1111/resp.12990</identifier><identifier>PMID: 28166610</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Administration, Oral ; Allergic diseases ; Alveoli ; animal models ; Animals ; Asthma ; Asthma - immunology ; Asthma - prevention & control ; Bronchoalveolar Lavage Fluid ; Bronchus ; Cell number ; Disease Models, Animal ; Eosinophils - immunology ; Epithelial cells ; Inflammation ; Interferon-gamma - immunology ; Interleukin 10 ; Interleukin 13 ; Interleukin 4 ; Interleukin 5 ; Interleukin-10 - immunology ; Interleukin-13 - immunology ; Interleukin-17 - immunology ; Interleukin-4 - immunology ; Leukocytes (eosinophilic) ; Lung - immunology ; Lung - physiopathology ; Lungs ; Male ; Mice ; Mice, Inbred BALB C ; Oral administration ; Ovalbumin ; primary prevention ; Probiotics ; Respiratory function ; Respiratory Hypersensitivity - immunology ; Respiratory Hypersensitivity - prevention & control ; Respiratory tract ; Rodents ; Saccharomyces cerevisiae ; Yeast</subject><ispartof>Respirology (Carlton, Vic.), 2017-07, Vol.22 (5), p.905-912</ispartof><rights>2017 Asian Pacific Society of Respirology</rights><rights>2017 Asian Pacific Society of Respirology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3570-8171d8df8c8c16538b54aae5f8b2ffa04fbbf8b9ecb084a57ac8a449f1a082ea3</citedby><cites>FETCH-LOGICAL-c3570-8171d8df8c8c16538b54aae5f8b2ffa04fbbf8b9ecb084a57ac8a449f1a082ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fresp.12990$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fresp.12990$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28166610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fonseca, Vanessa M.B.</creatorcontrib><creatorcontrib>Milani, Thamires M.S.</creatorcontrib><creatorcontrib>Prado, Rafael</creatorcontrib><creatorcontrib>Bonato, Vania L.D.</creatorcontrib><creatorcontrib>Ramos, Simone G.</creatorcontrib><creatorcontrib>Martins, Flaviano S.</creatorcontrib><creatorcontrib>Vianna, Elcio O.</creatorcontrib><creatorcontrib>Borges, Marcos de C.</creatorcontrib><title>Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice</title><title>Respirology (Carlton, Vic.)</title><addtitle>Respirology</addtitle><description>ABSTRACT
Background and objective
The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyces cerevisiae UFMG A‐905 in an allergic model of asthma.
Methods
Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, 1 week apart and challenged with OVA intranasally for 3 days. Mice were daily treated with S. cerevisiae UFMG A‐905 via gavaging needle 10 days before OVA sensitization and during challenges. After challenge, in vivo lung function was measured, and bronchoalveolar lavage (BAL) and lung inflammation were assessed.
Results
Oral treatment with S. cerevisiae UFMG A‐905 significantly decreased airway hyperresponsiveness, total cell number and the influx of eosinophils to the airway, inflammatory cell in the lung, mucus expression in epithelial cells and the levels of IL‐4, IL‐5 and IL‐13. Additionally, S. cerevisiae UFMG A‐905 restored the levels of IL‐10 and interferon (IFN)‐gamma, and increased the levels of IL‐17A.
Conclusion
Oral administration of S. cerevisiae UFMG A‐905 prevented the development of major asthma‐like characteristics in a mouse model.
Probiotics are a promising strategy for asthma prevention. We evaluated the effects of a yeast probiotic in ovalbumin‐challenged mice. Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevented the development of main asthma‐like characteristics, such as bronchial hyperresponsiveness, bronchoalveolar eosinophilia and airway and lung inflammation.</description><subject>Administration, Oral</subject><subject>Allergic diseases</subject><subject>Alveoli</subject><subject>animal models</subject><subject>Animals</subject><subject>Asthma</subject><subject>Asthma - immunology</subject><subject>Asthma - prevention & control</subject><subject>Bronchoalveolar Lavage Fluid</subject><subject>Bronchus</subject><subject>Cell number</subject><subject>Disease Models, Animal</subject><subject>Eosinophils - immunology</subject><subject>Epithelial cells</subject><subject>Inflammation</subject><subject>Interferon-gamma - immunology</subject><subject>Interleukin 10</subject><subject>Interleukin 13</subject><subject>Interleukin 4</subject><subject>Interleukin 5</subject><subject>Interleukin-10 - immunology</subject><subject>Interleukin-13 - immunology</subject><subject>Interleukin-17 - immunology</subject><subject>Interleukin-4 - immunology</subject><subject>Leukocytes (eosinophilic)</subject><subject>Lung - immunology</subject><subject>Lung - physiopathology</subject><subject>Lungs</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Oral administration</subject><subject>Ovalbumin</subject><subject>primary prevention</subject><subject>Probiotics</subject><subject>Respiratory function</subject><subject>Respiratory Hypersensitivity - immunology</subject><subject>Respiratory Hypersensitivity - prevention & control</subject><subject>Respiratory tract</subject><subject>Rodents</subject><subject>Saccharomyces cerevisiae</subject><subject>Yeast</subject><issn>1323-7799</issn><issn>1440-1843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKBDEQRYMovjd-gATciNCapJPu9FLEFyiKj6WE6kxFI_0Ykx5ldn6C3-iXGB114cLa1KU4XIpDyAZnuzzNXsA43uWiqtgcWeZSsoxrmc-nnIs8K8uqWiIrMT4yxnLF1CJZEpoXRcHZMrm7CNBQGLW-83EIMPi-o72j12DtA4S-nVqM1GLAZx89IL09Oj-m---vbxVTdJzO2A2RQtNguPeWQhweWqC-o623uEYWHDQR17_3Krk9Orw5OMnOLo5PD_bPMpurkmWal3ykR05bbXmhcl0rCYDK6Vo4B0y6uk65QlszLUGVYDVIWTkOTAuEfJVsz3rHoX-aYBxM66PFpoEO-0k0XBdKCya5SOjWH_Sxn4QufWd4JZhSQqgyUTszyoY-xoDOjINvIUwNZ-ZTuvmUbr6kJ3jzu3JStzj6RX8sJ4DPgBff4PSfKnN1eH05K_0AUmuNRQ</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Fonseca, Vanessa M.B.</creator><creator>Milani, Thamires M.S.</creator><creator>Prado, Rafael</creator><creator>Bonato, Vania L.D.</creator><creator>Ramos, Simone G.</creator><creator>Martins, Flaviano S.</creator><creator>Vianna, Elcio O.</creator><creator>Borges, Marcos de C.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201707</creationdate><title>Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice</title><author>Fonseca, Vanessa M.B. ; Milani, Thamires M.S. ; Prado, Rafael ; Bonato, Vania L.D. ; Ramos, Simone G. ; Martins, Flaviano S. ; Vianna, Elcio O. ; Borges, Marcos de C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3570-8171d8df8c8c16538b54aae5f8b2ffa04fbbf8b9ecb084a57ac8a449f1a082ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Allergic diseases</topic><topic>Alveoli</topic><topic>animal models</topic><topic>Animals</topic><topic>Asthma</topic><topic>Asthma - immunology</topic><topic>Asthma - prevention & control</topic><topic>Bronchoalveolar Lavage Fluid</topic><topic>Bronchus</topic><topic>Cell number</topic><topic>Disease Models, Animal</topic><topic>Eosinophils - immunology</topic><topic>Epithelial cells</topic><topic>Inflammation</topic><topic>Interferon-gamma - immunology</topic><topic>Interleukin 10</topic><topic>Interleukin 13</topic><topic>Interleukin 4</topic><topic>Interleukin 5</topic><topic>Interleukin-10 - immunology</topic><topic>Interleukin-13 - immunology</topic><topic>Interleukin-17 - immunology</topic><topic>Interleukin-4 - immunology</topic><topic>Leukocytes (eosinophilic)</topic><topic>Lung - immunology</topic><topic>Lung - physiopathology</topic><topic>Lungs</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Oral administration</topic><topic>Ovalbumin</topic><topic>primary prevention</topic><topic>Probiotics</topic><topic>Respiratory function</topic><topic>Respiratory Hypersensitivity - immunology</topic><topic>Respiratory Hypersensitivity - prevention & control</topic><topic>Respiratory tract</topic><topic>Rodents</topic><topic>Saccharomyces cerevisiae</topic><topic>Yeast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fonseca, Vanessa M.B.</creatorcontrib><creatorcontrib>Milani, Thamires M.S.</creatorcontrib><creatorcontrib>Prado, Rafael</creatorcontrib><creatorcontrib>Bonato, Vania L.D.</creatorcontrib><creatorcontrib>Ramos, Simone G.</creatorcontrib><creatorcontrib>Martins, Flaviano S.</creatorcontrib><creatorcontrib>Vianna, Elcio O.</creatorcontrib><creatorcontrib>Borges, Marcos de C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Respirology (Carlton, Vic.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fonseca, Vanessa M.B.</au><au>Milani, Thamires M.S.</au><au>Prado, Rafael</au><au>Bonato, Vania L.D.</au><au>Ramos, Simone G.</au><au>Martins, Flaviano S.</au><au>Vianna, Elcio O.</au><au>Borges, Marcos de C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice</atitle><jtitle>Respirology (Carlton, Vic.)</jtitle><addtitle>Respirology</addtitle><date>2017-07</date><risdate>2017</risdate><volume>22</volume><issue>5</issue><spage>905</spage><epage>912</epage><pages>905-912</pages><issn>1323-7799</issn><eissn>1440-1843</eissn><abstract>ABSTRACT
Background and objective
The prevalence of asthma has increased in communities that adopt a Western lifestyle and become more urbanized. Probiotics may be effective in the prevention of allergic diseases, such as asthma. The aim of the current study was to examine the effects of Saccharomyces cerevisiae UFMG A‐905 in an allergic model of asthma.
Methods
Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, 1 week apart and challenged with OVA intranasally for 3 days. Mice were daily treated with S. cerevisiae UFMG A‐905 via gavaging needle 10 days before OVA sensitization and during challenges. After challenge, in vivo lung function was measured, and bronchoalveolar lavage (BAL) and lung inflammation were assessed.
Results
Oral treatment with S. cerevisiae UFMG A‐905 significantly decreased airway hyperresponsiveness, total cell number and the influx of eosinophils to the airway, inflammatory cell in the lung, mucus expression in epithelial cells and the levels of IL‐4, IL‐5 and IL‐13. Additionally, S. cerevisiae UFMG A‐905 restored the levels of IL‐10 and interferon (IFN)‐gamma, and increased the levels of IL‐17A.
Conclusion
Oral administration of S. cerevisiae UFMG A‐905 prevented the development of major asthma‐like characteristics in a mouse model.
Probiotics are a promising strategy for asthma prevention. We evaluated the effects of a yeast probiotic in ovalbumin‐challenged mice. Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevented the development of main asthma‐like characteristics, such as bronchial hyperresponsiveness, bronchoalveolar eosinophilia and airway and lung inflammation.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>28166610</pmid><doi>10.1111/resp.12990</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1323-7799 |
| ispartof | Respirology (Carlton, Vic.), 2017-07, Vol.22 (5), p.905-912 |
| issn | 1323-7799 1440-1843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1865820412 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Allergic diseases Alveoli animal models Animals Asthma Asthma - immunology Asthma - prevention & control Bronchoalveolar Lavage Fluid Bronchus Cell number Disease Models, Animal Eosinophils - immunology Epithelial cells Inflammation Interferon-gamma - immunology Interleukin 10 Interleukin 13 Interleukin 4 Interleukin 5 Interleukin-10 - immunology Interleukin-13 - immunology Interleukin-17 - immunology Interleukin-4 - immunology Leukocytes (eosinophilic) Lung - immunology Lung - physiopathology Lungs Male Mice Mice, Inbred BALB C Oral administration Ovalbumin primary prevention Probiotics Respiratory function Respiratory Hypersensitivity - immunology Respiratory Hypersensitivity - prevention & control Respiratory tract Rodents Saccharomyces cerevisiae Yeast |
| title | Oral administration of Saccharomyces cerevisiae UFMG A‐905 prevents allergic asthma in mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A59%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20administration%20of%20Saccharomyces%20cerevisiae%20UFMG%20A%E2%80%90905%20prevents%20allergic%20asthma%20in%20mice&rft.jtitle=Respirology%20(Carlton,%20Vic.)&rft.au=Fonseca,%20Vanessa%20M.B.&rft.date=2017-07&rft.volume=22&rft.issue=5&rft.spage=905&rft.epage=912&rft.pages=905-912&rft.issn=1323-7799&rft.eissn=1440-1843&rft_id=info:doi/10.1111/resp.12990&rft_dat=%3Cproquest_cross%3E1865820412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920552257&rft_id=info:pmid/28166610&rfr_iscdi=true |